Dr Pedro Rocha speaks to ecancer about the phase 3 DeLLphi-304 trial, data from which was presented at ESMO 2025.

The trial previously showed that tarlatamab has superior overall survival and higher response rates compared to standard chemotherapy in patients with second-line small cell lung cancer (SCLC).

In the analysis Dr Rocha presented, benefits were consistent across subgroups, including those with short chemotherapy-free intervals and prior anti–PD-(L)1 therapy.

Tarlatamab also showed fewer severe treatment-related adverse events and lower rates of dose modification.

These findings confirm tarlatamab’s durable efficacy and favourable safety profile, reinforcing its standard of care status in relapsed SCLC.